Compare Ginkgo Bioworks Holdings Inc (DNA) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

VGT trades at $127.00, down 1.83% today but maintains a bullish technical outlook with strong moving average support. The ETF's focus on pure-play technology stocks like Nvidia, Apple, and Microsoft has delivered exceptional historical returns, averaging over 17% annually for two decades according to The Motley Fool (2026-10-03). Recent institutional buying activity signals continued confidence in the tech sector's growth prospects.

While VGT offers concentrated tech exposure with low fees, investors face sector concentration risk and potential AI slowdown concerns. The ETF's exclusion of major tech names like Google and Amazon due to classification rules creates unexpected portfolio gaps. Current technical strength supports near-term upside, but macroeconomic headwinds could pressure tech valuations.